News for Eisai Co., Ltd. (ESALY)

Published at

Apr 16, 2025 2:00 AM

by gurufocus.com

positive

positive

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia

IDP.DE ESALY ESALF BIIBD.BA BIIBCL.SN BIIB.SN BIIB.MX BIIB.BA BIIB 4523.T

Read more →
Published at

Apr 16, 2025 1:08 AM

by manilatimes.net

mixed

mixed

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union

**media[596172,596173]**

ESALY ESALF 4523.T IDP.DE BIIBD.BA BIIBCL.SN BIIB.SN BIIB.MX BIIB.BA BIIB

Read more →
Published at

Mar 27, 2025 12:20 PM

by manilatimes.net

mixed

mixed

BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

**media[578202]**

ESALY ESALF BYSI 4523.T LLY.MX LLY.DE LLY.BA LLY LILY34.SA 0Q1G.L

Read more →
Published at

Mar 24, 2025 2:00 PM

by gurufocus.com

positive

positive

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

Boston (March 24, 2025)””Allarity Therapeutics, Inc. (”Allarity” or the ”Company”) ( ALLR), a Phase 2 clinical-stage pharmaceutical company de

ESALY ESALF 4523.T

Read more →
Published at

Mar 17, 2025 2:00 PM

by gurufocus.com

positive

positive

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology

The Annual Meeting is the foremost educational and scientific event for gynecologic oncologistsStenoparib has shown clinical benefit in heavily pre-treate

ESALY ESALF 4523.T

Read more →
Published at

Mar 13, 2025 3:00 PM

by gurufocus.com

positive

positive

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Boston (March 13, 2025)””Allarity Therapeutics, Inc. (”Allarity” or the ”Company”) ( ALLR), a Phase 2 clinical-stage pharmaceutical company dedicate

ESALY ESALF 4523.T

Read more →
Published at

Mar 13, 2025 1:56 PM

by manilatimes.net

positive

positive

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

**media[565582]**

ESALY ESALF 4523.T

Read more →
Published at

Mar 6, 2025 2:09 PM

by manilatimes.net

mixed

mixed

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

**media[559052]**

ESALY ESALF 4523.T FRGAP

Read more →
Published at

Mar 3, 2025 2:00 PM

by gurufocus.com

positive

positive

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program

Boston (March 3, 2025)””Allarity Therapeutics, Inc. (”Allarity” or the ”Company”) ( ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated

ESALY ESALF 4523.T

Read more →
Published at

Feb 28, 2025 3:02 PM

by gurufocus.com

positive

positive

Biogen Inc (BIIB) and Eisai's Lecanemab Receives Positive Reaffirmation from European Medicines Agency

Biogen Inc (BIIB) and Eisai Co., Ltd. announced on February 28, 2025, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines A

IDP.DE ESALY ESALF BIIBD.BA BIIBCL.SN BIIB.SN BIIB.MX BIIB.BA BIIB 4523.T

Read more →
Published at

Feb 28, 2025 3:00 PM

by gurufocus.com

positive

positive

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

PR NewswireTOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: H

IDP.DE ESALY ESALF BIIBD.BA BIIBCL.SN BIIB.SN BIIB.MX BIIB.BA BIIB 4523.T

Read more →
Published at

Feb 26, 2025 2:00 PM

by gurufocus.com

positive

positive

Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit

Boston (February 26, 2025)””Allarity Therapeutics, Inc. (”Allarity” or the ”Company”) ( ALLR), a Phase 2 clinical-stage pharmaceutical company dedicate

ESALY ESALF 4523.T

Read more →
Published at

Feb 24, 2025 2:00 PM

by gurufocus.com

positive

positive

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance stenoparib and the stenoparib-DRP C

ESALY ESALF 4523.T

Read more →
Published at

Feb 14, 2025 3:08 PM

by manilatimes.net

positive

positive

Ensho Therapeutics Announces Upcoming Presentation at ECCO 2025 of Phase 1, Once-Daily Dosing Data for NSHO-101, an Oral α4β7 Inhibitor for Inflammatory Bowel Disease

**media[540845]**

ESALY ESALF 4523.T

Read more →
Published at

Feb 10, 2025 11:00 AM

by gurufocus.com

neutral

neutral

Q3 2025 Eisai Co Ltd Earnings Presentation Transcript

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O N4523.T - Eisai Co LtdQ3 2025 Eisai Co Ltd Earnings PresentationFeb 07, 2025 / 06:00AM GMT ====

ESALY ESALF 4523.T

Read more →
Published at

Feb 8, 2025 6:45 AM

by seekingalpha.com

mixed

mixed

Eisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript

Eisai Co., Ltd. (OTCPK:ESALF) Q3 2024 Earnings Call Transcript February 7, 2025 1:00 AM ETCompany ParticipantsHaruo Naito - Representative Corporate Officer...

MSCL.SN ESALY ESALF 4523.T

Read more →
Published at

Feb 6, 2025 2:21 PM

by manilatimes.net

positive

positive

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

**media[534054]**

ESALY ESALF 4523.T

Read more →
Published at

Feb 2, 2025 2:12 PM

by insidermonkey.com

positive

positive

Why Are Analysts Bullish on Biogen Inc. (BIIB) Now?

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Biogen Inc.

IDP.DE ESALY ESALF BIIBD.BA BIIBCL.SN BIIB.SN BIIB.MX BIIB.BA BIIB 4523.T

Read more →
Published at

Jan 31, 2025 12:38 PM

by manilatimes.net

positive

positive

Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

**media[528937,528938]**

IDP.DE ESALY ESALF BIIBD.BA BIIBCL.SN BIIB.SN BIIB.MX BIIB.BA BIIB 4523.T

Read more →
Published at

Jan 31, 2025 12:33 PM

by financialpost.com

positive

positive

Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corpo…

IDP.DE ESALY ESALF BIIBD.BA BIIBCL.SN BIIB.SN BIIB.MX BIIB.BA BIIB 4523.T

Read more →